EMI 400

Drug Profile

EMI 400

Alternative Names: EMI-400

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Edinburgh Molecular Imaging
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 16 Feb 2017 Preclinical trials in Pulmonary fibrosis (Diagnosis) in United Kingdom (Parenteral) before February 2017 (Edinburgh Molecular Imaging pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top